Thursday, October 13, 2016 3:10:41 PM
RDAR 0.0001/18M x 0.0002/105M
Bid | Size
0.0001 | 17,999,900
Ask | Size
0.0002 | 105,354,800
Targets 0.0005 / 0.0006
http://www.otcmarkets.com/stock/RDAR/profile
http://www.otcmarkets.com/stock/RDAR/news
http://www.otcmarkets.com/stock/RDAR/filings
Business Entity Information
Actions\Amendments
http://nvsos.gov/sosentitysearch/CorpDetails.aspx?lx8nvq=kVbWZWwNaxAgAJOzD5in3g%253d%253d&nt7=0
http://nvsos.gov/sosentitysearch/corpActions.aspx?lx8nvq=kVbWZWwNaxAgAJOzD5in3g%253d%253d&CorpName=RAADR%2c+INC.
News / Targets
http://www.allotcbb.com/quote.php?symbol=rdar
Time and Sales
http://www.investorpoint.com/stock/RDAR-RAADR+Inc/market-makers-level2/
http://www.investorpoint.com/stock/RDAR-RAADR+Inc/price-history/
Short Information
http://otcshortreport.com/?index=RDAR&action=view
http://www.otcmarkets.com/stock/RDAR/short-sales
http://shortsqueeze.com/?symbol=rdar&submit=Short+Quote%E2%84%A2
https://www.interactivebrokers.com/en/index.php?key=rdar&cntry=usa&tag=United+States&ib_entity=llc&ln=&asset=&f=4587&conf=am&amref=1
Recent RDAR News
- Form 1-A POS - • Edgar (US Regulatory) • 02/28/2024 06:04:50 PM
- Form 1-A POS - • Edgar (US Regulatory) • 01/12/2024 10:24:12 PM
- Form 253G2 - • Edgar (US Regulatory) • 12/29/2023 09:12:20 PM
- Form 253G1 - • Edgar (US Regulatory) • 10/16/2023 01:28:37 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 10/16/2023 04:15:08 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/03/2023 05:20:48 PM
FEATURED Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • BLOZF • May 7, 2024 8:51 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM